Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02362503
Registration number
NCT02362503
Ethics application status
Date submitted
9/02/2015
Date registered
13/02/2015
Date last updated
30/01/2024
Titles & IDs
Public title
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
Query!
Scientific title
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Query!
Secondary ID [1]
0
0
AI438-047
Query!
Secondary ID [2]
0
0
205888
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
HIV Infections
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Acquired immune deficiency syndrome (AIDS / HIV)
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - BMS-663068
Other interventions - Placebo
Experimental: A1: BMS-663068 - Phase 1: BMS-663068 600 mg tablets orally twice daily for 8 days. Phase 2: BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.
Active Comparator: B1: Placebo + BMS-663068 - Phase 1: Placebo twice daily for 8 days. Phase 2: BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.
Experimental: BMS-663068 - BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.
Treatment: Drugs: BMS-663068
BMS-663068
Other interventions: Placebo
Placebo
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Mean Change in Logarithm to the Base 10 (log10) HIV-1 Ribonucleic Acid (RNA) From Day 1 at Day 8-Randomized Cohort
Query!
Assessment method [1]
0
0
Plasma samples were collected for analysis of HIV-1 RNA. Mean change in log10 HIV-1 RNA from Day 1 was estimated using analysis of covariance (ANCOVA) with log10 HIV-1 RNA change from Day 1 at Day 8 as dependent variable, treatment (fostemsavir or placebo) as an independent variable, and Day 1 log10 HIV-1 RNA as a continuous covariate. Change from Day 1 was calculated as value at Day 8 minus value at Day 1. The analysis was performed on Intent-to-Treat Exposed (ITT-E) Population which comprised of all randomized participants who received at least one dose of study treatment. Missing HIV-1 RNA values at Day 8 were imputed using (a) Day 1 Observation Carried Forward (D1OCF) for participants without a value during blinded treatment (i.e, imputing a zero change from Day 1) or (b) Last Observation Carried Forward (LOCF) for participants with an early value during blinded treatment before the Day 8 analysis visit window.
Query!
Timepoint [1]
0
0
Day 1 and Day 8
Query!
Secondary outcome [1]
0
0
Percentage of Participants With HIV-1 RNA Decreases From Day 1 That Exceed 0.5 log10 c/mL and 1.0 log10 c/mL at Day 8-Randomized Cohort
Query!
Assessment method [1]
0
0
The percentage of participants in the Randomized Cohort with HIV-1 RNA decreases from Day 1 that exceed 0.5 log10 c/mL and 1.0 log10 c/mL at Day 8 was determined by comparing HIV-1 RNA Day 1 measurement of each participant to their Day 8 measurement. This was an ITT analysis that classified participants without HIV-1 RNA at Day 1 or Day 8 as failures. The percentage of responders along with 95% confidence interval based on Wilson score is presented.
Query!
Timepoint [1]
0
0
Day 1 and Day 8
Query!
Secondary outcome [2]
0
0
Percentage of Participants With HIV-1 RNA <40 c/mL at Weeks 24, 48 and 96-Randomized Cohort
Query!
Assessment method [2]
0
0
The durability of response (that is, the number of participants achieving HIV-1 RNA <40 c/mL) at Weeks 24, 48 and 96 of open-label fostemsavir plus OBT in the Randomized Cohort was assessed using the Food and Drug Administration (FDA) snapshot algorithm in which participants without HIV-1 RNA at Weeks 24, 48 and 96 or those who changed OBT due to lack of efficacy through Weeks 24, 48 and 96 were counted as failures. The percentage of participants in the Randomized Cohort who achieved virologic success (HIV-1 RNA <40 c/mL) at Weeks 24, 48 and 96 is presented along with 95% Wilson confidence interval. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.
Query!
Timepoint [2]
0
0
At Weeks 24, 48 and 96
Query!
Secondary outcome [3]
0
0
Number of Participants With On-treatment Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Discontinuation (AELD)-Randomized Cohort
Query!
Assessment method [3]
0
0
An SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or causes prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; an important medical event that may jeopardize the participant or require intervention. Number of participants with on-treatment SAEs and AEs leading to withdrawal of study treatment is presented. SAEs and AELDs were collected in Safety Population which comprised of all participants who received at least one dose of study treatment. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.
Query!
Timepoint [3]
0
0
Up to Week 96 analysis cut-off date
Query!
Secondary outcome [4]
0
0
Number of Participants With Toxicity Grade Increase in Clinical Chemistry Results to Grade 3-4 Relative to Baseline-Randomized Cohort
Query!
Assessment method [4]
0
0
Laboratory toxicities were graded for severity according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) grading system: Grade 1 (mild); Grade 2 (moderate); Grade 3 (severe); Grade 4 (potentially life-threatening). Baseline is defined as the latest pre-dose assessment. The number of participants with clinical chemistry toxicity grade increase to Grade 3-4 at anytime post-Baseline relative to Baseline is presented. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.
Query!
Timepoint [4]
0
0
Baseline and up to Week 96 analysis cut-off date
Query!
Secondary outcome [5]
0
0
Number of Participants With Toxicity Grade Increase in Hematology Results to Grade 3-4 Relative to Baseline-Randomized Cohort
Query!
Assessment method [5]
0
0
Laboratory toxicities were graded for severity according to the DAIDS grading system: Grade 1 (mild); Grade 2 (moderate); Grade 3 (severe); Grade 4 (potentially life-threatening). Baseline is defined as the latest pre-dose assessment. The number of participants with hematology toxicity grade increase to Grade 3-4 at anytime post-Baseline relative to Baseline is presented. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.
Query!
Timepoint [5]
0
0
Baseline and up to Week 96 analysis cut-off date
Query!
Secondary outcome [6]
0
0
Number of Participants With Centers for Disease Control (CDC) Class C Events-Randomized Cohort
Query!
Assessment method [6]
0
0
Disease progression during open label fostemsavir plus OBT was assessed based on the occurrence of new AIDS defining events (CDC Class C events) or death. The number of participants with on-treatment CDC Class C AIDS events is presented. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.
Query!
Timepoint [6]
0
0
Up to Week 96 analysis cut-off date
Query!
Secondary outcome [7]
0
0
Change From Day 1 in Cluster of Differentiation (CD) 4+ T-cell Count at Day 8-Randomized Cohort
Query!
Assessment method [7]
0
0
CD4+ T- cell counts were assessed by flow cytometry. Mean change in CD4+ T- cell count from Day 1 at Day 8 was analyzed using one-way ANCOVA with change of CD4+ cell counts from Day 1 at Day 8 as the dependent variable, treatment (fostemsavir or placebo) as an in-dependent variable, and Day 1 CD4+ cell count as a continuous covariate. Change from Day 1 was calculated as value at Day 8 minus value at Day 1. Missing CD4+ cell count values at Day 8 were imputed using (a) D1OCF for participants without a value during blinded treatment (i.e., imputing a zero change from Day 1), or (b) LOCF for participants with an early value during blinded treatment before the Day 8 analysis visit window.
Query!
Timepoint [7]
0
0
Day 1 and Day 8
Query!
Secondary outcome [8]
0
0
Change in CD4+ T- Cell Count Percentage From Day 1 at Day 8-Randomized Cohort
Query!
Assessment method [8]
0
0
CD4+ T- cell counts were assessed by flow cytometry. Mean change in CD4+ T- cell count percentage from Day 1 at Day 8 was analyzed using one-way ANCOVA with change of CD4+ cell count percentage from Day 1 at Day 8 as the dependent variable, treatment (fostemsavir or placebo) as an independent variable, and Day 1 CD4+ cell count percentage as a continuous covariate. Change from Day 1 was calculated as value at Day 8 minus value at Day 1. Missing CD4+ cell count values at Day 8 were imputed using (a) D1OCF for participants without a value during blinded treatment (ie, imputing a zero change from Day 1), or (b) LOCF for participants with an early value during blinded treatment before the Day 8 analysis visit window.
Query!
Timepoint [8]
0
0
Day 1 and Day 8
Query!
Secondary outcome [9]
0
0
Change From Baseline in log10 HIV-1 RNA for Fostemsavir When Given With OBT Through Week 96-Randomized Cohort
Query!
Assessment method [9]
0
0
Blood samples were collected for the analysis of HIV-1 RNA. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as the value at post-dose visit minus the value at Baseline. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.
Query!
Timepoint [9]
0
0
Baseline and at Day 8, Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84 and 96
Query!
Secondary outcome [10]
0
0
Change From Baseline in CD4+ T- Cell Count Through Week 96-Randomized Cohort
Query!
Assessment method [10]
0
0
CD4+ T- cell counts were assessed by flow cytometry. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as the value at post-dose visit minus the value at Baseline.
Query!
Timepoint [10]
0
0
Baseline and at Day 8, Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84 and 96
Query!
Secondary outcome [11]
0
0
Change From Baseline in CD4+ T- Cell Count Percentage Through Week 96
Query!
Assessment method [11]
0
0
Percentage CD4+ T- cell counts were assessed by flow cytometry. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as the value at post-dose visit minus the value at Baseline.
Query!
Timepoint [11]
0
0
Baseline and at Day 8, Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84 and 96
Query!
Secondary outcome [12]
0
0
Number of Participants With Treatment-emergent Viral Genotypic Substitution of Interest in the GP160 Domain as a Measure of Genotypic Resistance-Randomized Cohort
Query!
Assessment method [12]
0
0
Plasma samples were collected for emergent drug resistance testing. The number of participants with emergent viral genotypic substitutions of interest in the GP160 domain was identified by the next-generation sequencing (NGS) assay. Protocol defined virologic failure (PDVF) through Week 96 Population comprised of all participants with available phenotypic and genotypic resistance data meeting at the time protocol defined virologic failure (PDVF) was met. The criteria for PDVF was a) Confirmed, or last available prior to discontinuation, HIV-1 RNA >=400 c/mL at any time after prior confirmed suppression to <400 c/mL prior to Week 24 or Confirmed, or last available prior to discontinuation, > 1 log10 c/mL increase in HIV-1 RNA at any time above nadir level where nadir is >=40 c/mL prior to Week 24. b) Confirmed, or last available prior to discontinuation, HIV-1 RNA >=400 c/mL at or after Week 24.
Query!
Timepoint [12]
0
0
Week 96
Query!
Secondary outcome [13]
0
0
Number of Participants With Indicated Fold Change Ratio (FCR) Using the Monogram PhenoSense Entry Assay-Randomized Cohort
Query!
Assessment method [13]
0
0
The phenotypic resistance to a drug is defined in terms of a fold change (FC) in IC50s, i.e., the ratio of the 50% inhibitory concentration (IC50) of the clinical isolate to the IC50 of a reference strain (wild type control). FCR was calculated as FC at PDVF divided by Baseline FC. The number of participants with the indicated change (ratio) in the two values at the time of PDVF is presented. FCR<1 indicates that FC is smaller on-treatment than at Baseline. FCR >3 indicates that on-treatment FC is 3 times greater than it was at Baseline.
Query!
Timepoint [13]
0
0
Week 96
Query!
Eligibility
Key inclusion criteria
- Men and non-pregnant women with chronic HIV-1 infection
- Antiretroviral-experienced with documented historical or baseline resistance,
intolerability, and/or contraindications to antiretrovirals in at least three classes
- Failing current antiretroviral regimen with a confirmed plasma HIV-1 RNA = 400 c/mL
(first value from Investigator, second from Screening labs)
- Must have = 2 classes with at least 1 but no more than 2 fully-active antiretrovirals
remaining which can be effectively combined to form a viable new regimen, based on
current and/or documented historical resistance testing and tolerability and safety
- Able to receive = 1 fully active approved antiretroviral as part of the OBT from Day 9
onwards in the Randomized Cohort
- Subjects without any remaining fully active approved antiretroviral may be enrolled in
the Non-Randomized Cohort
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Chronic untreated Hepatitis B virus (HBV) (however, patients with chronic treated HBV
are eligible)
- HIV-2 infection
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 7 x ULN
- Alkaline Phosphatase > 5 x ULN
- Bilirubin = 1.5 x Upper limit of normal (ULN) (unless subject is currently on
atazanavir and has predominantly unconjugated hyperbilirubinemia)
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
23/02/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
31/12/2025
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
371
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - Darlinghurst
Query!
Recruitment hospital [2]
0
0
GSK Investigational Site - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [2]
0
0
3004 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
District of Columbia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Indiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Maryland
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Massachusetts
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Michigan
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New Jersey
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New York
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
North Carolina
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Ohio
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Oklahoma
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Pennsylvania
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Texas
Query!
Country [19]
0
0
Argentina
Query!
State/province [19]
0
0
Buenos Aires
Query!
Country [20]
0
0
Argentina
Query!
State/province [20]
0
0
Córdova
Query!
Country [21]
0
0
Argentina
Query!
State/province [21]
0
0
Santa Fe
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Antwerpen
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Brussels
Query!
Country [24]
0
0
Brazil
Query!
State/province [24]
0
0
Paraná
Query!
Country [25]
0
0
Brazil
Query!
State/province [25]
0
0
Rio Grande Do Sul
Query!
Country [26]
0
0
Brazil
Query!
State/province [26]
0
0
São Paulo
Query!
Country [27]
0
0
Brazil
Query!
State/province [27]
0
0
Belo Horizonte
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
Ribeirao Preto
Query!
Country [29]
0
0
Brazil
Query!
State/province [29]
0
0
Rio de Janeiro
Query!
Country [30]
0
0
Brazil
Query!
State/province [30]
0
0
Salvador
Query!
Country [31]
0
0
Canada
Query!
State/province [31]
0
0
British Columbia
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
Ontario
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
Quebec
Query!
Country [34]
0
0
Canada
Query!
State/province [34]
0
0
Vancouver
Query!
Country [35]
0
0
Chile
Query!
State/province [35]
0
0
Región Metro De Santiago
Query!
Country [36]
0
0
Chile
Query!
State/province [36]
0
0
Santiago
Query!
Country [37]
0
0
Chile
Query!
State/province [37]
0
0
Temuco
Query!
Country [38]
0
0
Colombia
Query!
State/province [38]
0
0
Bogota
Query!
Country [39]
0
0
Colombia
Query!
State/province [39]
0
0
Bogotá
Query!
Country [40]
0
0
Colombia
Query!
State/province [40]
0
0
Cali, Valle Del Cauca
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Bordeaux cedex
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Marseille
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Nantes
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Paris cedex 10
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Paris Cedex 12
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Paris cedex 20
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Paris
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Baden-Wuerttemberg
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Hessen
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Nordrhein-Westfalen
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Berlin
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
München
Query!
Country [53]
0
0
Greece
Query!
State/province [53]
0
0
Athens
Query!
Country [54]
0
0
Greece
Query!
State/province [54]
0
0
Thessaloniki
Query!
Country [55]
0
0
Ireland
Query!
State/province [55]
0
0
Dublin
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Lazio
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
Lombardia
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Piemonte
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Modena
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Monza
Query!
Country [61]
0
0
Mexico
Query!
State/province [61]
0
0
Estado De México
Query!
Country [62]
0
0
Mexico
Query!
State/province [62]
0
0
Jalisco
Query!
Country [63]
0
0
Mexico
Query!
State/province [63]
0
0
Chihuahua
Query!
Country [64]
0
0
Mexico
Query!
State/province [64]
0
0
Ciudad de Mexico
Query!
Country [65]
0
0
Mexico
Query!
State/province [65]
0
0
Distrito Federal
Query!
Country [66]
0
0
Mexico
Query!
State/province [66]
0
0
Mexico
Query!
Country [67]
0
0
Netherlands
Query!
State/province [67]
0
0
Utrecht
Query!
Country [68]
0
0
Peru
Query!
State/province [68]
0
0
Loreto
Query!
Country [69]
0
0
Peru
Query!
State/province [69]
0
0
Lima
Query!
Country [70]
0
0
Poland
Query!
State/province [70]
0
0
Szczecin
Query!
Country [71]
0
0
Poland
Query!
State/province [71]
0
0
Warszawa
Query!
Country [72]
0
0
Portugal
Query!
State/province [72]
0
0
Lisboa
Query!
Country [73]
0
0
Portugal
Query!
State/province [73]
0
0
Lisbon
Query!
Country [74]
0
0
Puerto Rico
Query!
State/province [74]
0
0
San Juan
Query!
Country [75]
0
0
Romania
Query!
State/province [75]
0
0
Bucharest
Query!
Country [76]
0
0
Russian Federation
Query!
State/province [76]
0
0
Irkutsk
Query!
Country [77]
0
0
Russian Federation
Query!
State/province [77]
0
0
Krasnodar
Query!
Country [78]
0
0
South Africa
Query!
State/province [78]
0
0
Eastern Cape
Query!
Country [79]
0
0
South Africa
Query!
State/province [79]
0
0
Free State
Query!
Country [80]
0
0
South Africa
Query!
State/province [80]
0
0
Gauteng
Query!
Country [81]
0
0
South Africa
Query!
State/province [81]
0
0
KwaZulu- Natal
Query!
Country [82]
0
0
South Africa
Query!
State/province [82]
0
0
Western Province
Query!
Country [83]
0
0
South Africa
Query!
State/province [83]
0
0
Cape Town
Query!
Country [84]
0
0
South Africa
Query!
State/province [84]
0
0
Durban
Query!
Country [85]
0
0
Spain
Query!
State/province [85]
0
0
Badalona, Barcelona
Query!
Country [86]
0
0
Spain
Query!
State/province [86]
0
0
Barcelona
Query!
Country [87]
0
0
Spain
Query!
State/province [87]
0
0
Madrid
Query!
Country [88]
0
0
Spain
Query!
State/province [88]
0
0
Seville, Sevilla
Query!
Country [89]
0
0
Taiwan
Query!
State/province [89]
0
0
Taipei
Query!
Country [90]
0
0
United Kingdom
Query!
State/province [90]
0
0
Bournemouth
Query!
Country [91]
0
0
United Kingdom
Query!
State/province [91]
0
0
Leicestershire
Query!
Country [92]
0
0
United Kingdom
Query!
State/province [92]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
ViiV Healthcare
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to determine whether the BMS Attachment Inhibitor (BMS-663068)
is effective in the treatment of heavily treatment experienced HIV-1 patients with multi-drug
resistance.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02362503
Query!
Trial related presentations / publications
Kozal M, Aberg J, Pialoux G, Cahn P, Thompson M, Molina JM, Grinsztejn B, Diaz R, Castagna A, Kumar P, Latiff G, DeJesus E, Gummel M, Gartland M, Pierce A, Ackerman P, Llamoso C, Lataillade M; BRIGHTE Trial Team. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. N Engl J Med. 2020 Mar 26;382(13):1232-1243. doi: 10.1056/NEJMoa1902493.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
ViiV Healthcare
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02362503
Download to PDF